Chairperson

Enthusiast Gaming Advances Strategic Objectives with C$4.1 Million Sale of Select Non-Core Assets

Retrieved on: 
Monday, April 1, 2024
Luminosity Gaming, Enthusiasm, Partnership, Pocket Gamer, Chairperson, Shock wave, Sale, EGLX, TSX, Asset, Interim, Luminosity, NFL, Enthusiast Gaming

LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company, today announced it has entered into a definitive agreement (the “Asset Sale Agreement”) for the divestment of certain non-core and non-profitable casual gaming assets (the “Assets”) for a purchase price of approximately C$4.1 million.

Key Points: 
  • LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company, today announced it has entered into a definitive agreement (the “Asset Sale Agreement”) for the divestment of certain non-core and non-profitable casual gaming assets (the “Assets”) for a purchase price of approximately C$4.1 million.
  • The Assets comprise a subset of Enthusiast Gaming’s casual gaming business, and the divestment is a continuation of a number of recent strategic actions designed to enhance the Company’s operational efficiency while emphasizing high-margin revenue growth and sustainable profitability.
  • “We are swiftly executing on our strategic objectives including operational efficiency, enhancing liquidity, and building a platform of sustainable profitability,” said Adrian Montgomery, Board Chair and Interim CEO of Enthusiast Gaming.
  • “This sale of a subset of non-core and non-profitable assets for C$4.1 million underscores our dedication to strengthening our balance sheet while simultaneously reducing operating costs.

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, April 1, 2024
Lewy body, Research, GBA, Administration, Plasma, Conference, MRI, DLB, GFAP, Basal forebrain, Patient, Journal, Chairperson, Sale, TID, Manuscript, Public expenditure, Biomarker, Glial fibrillary acidic protein, MD, University College London, Atrophy, Publication, Frontotemporal dementia, Alpha-synuclein, NIA, Research and development, Vertex Pharmaceuticals, Axonal transport, Dementia, CRVO

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Moreover, the neflamapimod treatment effects on GFAP were correlated to clinical outcomes, assessed by the CDR-SB.
  • Cash Position: As of December 31, 2023, CervoMed had $7.8 million in cash and cash equivalents as compared to $4.1 million as of December 31, 2022.
  • This increase was attributed to the RewinD-LB Phase 2b clinical study in DLB which began in the first quarter of 2023.
  • Net Loss: Net Loss was $2.2 million for the year ended December 31, 2023, compared to a net loss of $5.8 million for year ended December 31, 2022.

Enthusiast Gaming Partners with Playwire to Amplify Monetization Opportunities Across its Communities

Retrieved on: 
Thursday, March 28, 2024
Organization, Partnership, Chairperson, EGLX, Make, Gaming, TSX, Interim, Trailblazer, NFL, Enthusiast Gaming, Video game

“Forging this partnership with Playwire provides Enthusiast Gaming with a world class adtech platform so that we can focus on our core -- building communities, and creating and curating content and experiences that engage gamers and esports fans,” said Board Chair and Interim CEO Adrian Montgomery. “The strategic initiative to outsource our adtech is a key element of our simplified and streamlined strategy. As a result of this partnership, along with other efficiency initiatives, we are well-positioned to deliver meaningful improvement in financial performance while continuing to serve our audience and brands.”

Key Points: 
  • LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming'' or the “Company”) (TSX: EGLX), the leading gaming and media company in North America, today announced a multi-year partnership with leading advertising technology provider Playwire.
  • Enthusiast Gaming will leverage RAMP®, Playwire’s complete Revenue Amplification Management Platform, to power Enthusiast Gaming’s network of gaming websites, channels and apps.
  • Playwire brings nearly two decades of experience helping enterprise organizations manage multiple sites and a strong legacy in gaming.
  • This will allow Enthusiast Gaming to optimize its programmatic performance and drive incremental revenue opportunities.

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Retrieved on: 
Thursday, March 28, 2024
Patient, Chairperson, CNS, Mental health, Innovation, CMPS, Psilocybin, TRD, Johnson & Johnson, Operation, Pain, KCL, Frustration, J&J, Food, Nursing

David Norton, lead independent director on the Compass board of directors, will become interim chair.

Key Points: 
  • David Norton, lead independent director on the Compass board of directors, will become interim chair.
  • Compass is running a global search for a permanent board chair, focused on recruiting a leader with a strong background in the biotechnology sector and broad strategic experience across the product lifecycle.
  • “When we started Compass eight years ago, we could not have imagined how the company would grow and mature,” said George Goldsmith, outgoing board chair of Compass Pathways.
  • He has been a member of the Compass board of directors since 2018, serving as lead independent director.

Mega Uranium Announces Results of Annual Shareholder Meeting

Retrieved on: 
Tuesday, March 26, 2024
University, Uranium, Thunderbird Entertainment, Ernst & Young, Entrepreneurship, General counsel, Tulane University Law School, Knowledge, Chairperson, Toronto International Film Festival, Cerebral palsy, Mining, CPA

At the meeting, shareholders also appointed Ernst & Young LLP as the company’s auditors, to hold office until the next annual meeting.

Key Points: 
  • At the meeting, shareholders also appointed Ernst & Young LLP as the company’s auditors, to hold office until the next annual meeting.
  • Complete voting results of the meeting are available under the company’s profile on sedar.com.
  • She currently serves on the boards and audit committees (including as Chair) of junior mining companies engaged in uranium and gold exploration.
  • Since 2014, she has dedicated her time to a grass roots charity she created which provides financial assistance to families with children with cerebral palsy.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

Retrieved on: 
Tuesday, March 26, 2024
Tao, Internal medicine, Professor, Patient, Pulmonology, Executive Committee, Drug, Therapy, Chairperson, Sensation, Genentech, NSW, St George's Hospital, Harvard University, MTR, Pediatrics, Stanford University, Teaching hospital, Critical care, Outline of health sciences, KCP, Neuroinflammation, UCSF, Research, Acquisition, University, Management, MPH, Drug development, Atopic dermatitis, Entrepreneurship, Critical Care Medicine (journal), Adolescence, Contact dermatitis, Science, Division, KRYS, Pharmaceutical industry

FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.

Key Points: 
  • Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ: KRYS), where he was Senior Vice President of Clinical Development.
  • At Attovia, Dr. Chen will lead the company’s clinical development and regulatory functions and will serve on the Executive Committee.
  • Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development.
  • To support the ongoing strategic development of the Attobody platform and advancement of the Company’s emerging pipeline candidates, Attovia has established Clinical and Scientific Advisory Boards comprised of biopharmaceutical industry veterans and academic experts.

Watts Water Technologies, Inc. Remembers the Life and Legacy of Donald Mullett, Former CEO of Bradley Company

Retrieved on: 
Monday, April 8, 2024
HVAC, Engineering, Other Manufacturing, Manufacturing, Growth, Heat, Education, News, Life, Water quality, Water, Chairperson, Safety, Multimedia, Family, Management

Watts Water Technologies, Inc. (NYSE: WTS) today shares news of the passing of Donald Mullett, former Chief Executive Officer of Bradley Company.

Key Points: 
  • Watts Water Technologies, Inc. (NYSE: WTS) today shares news of the passing of Donald Mullett, former Chief Executive Officer of Bradley Company.
  • Five generations of Mullett family leadership, and more than 100 years of growth, are a testament to their legacy.
  • Mr. Mullett was a visionary in the manufacturing industry, with his career at Bradley Company spanning 55 years.
  • Watts Water companies and brands offer innovative plumbing, heating, and water quality solutions to control the efficiency, safety, and quality of water within commercial, residential, and industrial applications.

DUANE LAWRENCE APPOINTED AS CHAIR OF THE ONETOUCH HEALTH GROUP BOARD

Retrieved on: 
Tuesday, April 9, 2024
Simplyhealth, Growth, Chairperson, Consortium, SME, Management

GALWAY, Ireland, April 9, 2024 /PRNewswire/ -- Duane Lawrence's extensive background includes spearheading global initiatives in AI diagnostics and care pathways as CEO at InferMed Limited, overseeing strategic digital marketing and SEO in the global healthtech and pharmaceutical sectors as Chairman at Spark Health, and expanding access to care with health-related financial services as Non Executive Director, SID and Chair of the Investment Committee at UK based Simplyhealth. Throughout his career, Duane has held pivotal roles as a CEO, Chairman, or Non-Executive Director for health tech SMEs, as well as mid-market publicly traded technology and service businesses across five continents.

Key Points: 
  • OneTouch Health Group, a leading player in the healthcare technology industry, proudly announces the appointment of Duane Lawrence as Chair.
  • Dermot Clancy, CEO of OneTouch Health Group, warmly welcomed Duane Lawrence, stating, "We are thrilled to welcome Duane as the new Chair of our Board.
  • Kishan Chotai and Katie Beckingham from August Equity, the investment firm backing OneTouch Health Group, expressed excitement about the appointment, saying, "Duane Lawrence brings a great blend of expertise and a proven track record in the healthcare technology industry.
  • Duane Lawrence shared his enthusiasm, stating, "I am honoured to join OneTouch Health Group as Chair of the Board.

Diego Rodriguez Nominated to Stand for Election to TrueCar's Board of Directors at May 23, 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Mechanical, Business administration, Chairperson, IDEO, Harvard Business School, Acquisition, Transport, Intuit, Stanford University, Bachelor, TrueCar, Fintech, Partnership, LendingTree, Annual general meeting, Management

Mr. Rodriguez would fill the vacancy created by Erin Lantz, who is retiring from service on the Board at the Annual Meeting.

Key Points: 
  • Mr. Rodriguez would fill the vacancy created by Erin Lantz, who is retiring from service on the Board at the Annual Meeting.
  • "On behalf of the entire board, I extend our heartfelt gratitude to Erin Lantz for eight years of dedicated service.
  • Her contributions have been invaluable, and we wish her the very best in her future endeavors," said Barbara Carbone, Board Chair.
  • He is currently a board member at LendingTree and was on the board of EngageSmart until its January 2024 acquisition.

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on: 
Monday, April 8, 2024
Clinical research, Stanford Cancer Institute, Hematology, Oncology, Associate, Caregiver, Colorectal cancer, Education, Chairperson, Patient, FACP, Research, NCCN, University, Cancer, Glomus tumor, Fox Chase Cancer Center, Leukemia, MBA, FRCP, MPH, Drug development, Health, Management

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points: 
  • PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
  • He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
  • "As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
  • "I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.